FFC#18/2020

Counteracting inflammation triggered by P. aeruginosa-activated lung-infiltrating Th1/17 cells: a novel approach for precision medicine in CF

AREA 4 Lung inflammation

FFC#18/2020

Counteracting inflammation triggered by P. aeruginosa-activated lung-infiltrating Th1/17 cells: a novel approach for precision medicine in CF
€ 0 still needed
0%
€ 85.000 goal

pRINCIPAL INVESTIGATOR

Moira Paroni (Università degli studi di Milano, Dip. di Bioscienze)

Partner

Helle Krogh Johansen (Technical University of Denmark, Rigshospitalet, Dep. of Clinical Microbiology)

Researchers

8

Category

AREA 4 Lung inflammation

Duration

2 years

Goal

€ 85.000

Funds raised

€ 85.000

Objectives

Pseudomonas aeruginosa (Pa) respiratory infection is accompanied by the immune system’s over-activation, followed by chronic inflammation that ends up severely damaging the CF lung. The anti-inflammatory drugs nowadays available cannot selectively target the pathogenic immune system’s response. To address this issue, it would be important to know the molecular mechanisms through which Pa and the immune system interact. A new class of T lymphocytes (Th1/17) has recently been discovered, which have shown to be excessively activated by Pa clinical strains isolated after years of persistence in the CF lungs. The aim of the project is to identify the molecular mechanisms that induce the proliferation of Th1/17 lymphocytes because of Pa. Thanks to functional immunological approaches and advanced molecular biology techniques, such as massive RNA sequencing, the Th1/17 lymphocyte’s genes and the Pa responsible for their activation will be studied. The prospect is to identify new therapeutic targets with the ultimate goal of finding a more selective, thus effective, anti-inflammatory drug.

WHO ADOPTED THE PROJECT

Delegazione FFC di Sassari Castelsardo con Gruppo di sostegno FFC di Siniscola Nuoro

€ 85.000

Latteria Montello

€ 15.000

Delegazione FFC di Novara

€ 8.000

OTHER PROJECTS

Discover the other projects

GMSG#1/2025

Developing PNAs to Block Essential Bacterial Genes and Create New Antimicrobial Therapies

FFC#1/2025

Understanding the process of epithelial-mesenchymal transition to preserve tissue function and reduce long-term complications (e.g. cancer)

FFC#2/2025

Developing RNA-targeted therapies to regulate gene expression and restore CFTR synthesis